Exit multiples are valuation ratios - most commonly EV/Revenue or EV/EBITDA - used to value a MedTech company at acquisition or IPO. Recent comparable transactions and public MedTech trading multiples set the benchmark. Exit multiples are often expressed as a multiple of revenue for device companies, since many are not yet profitable at acquisition. They vary by segment, growth rate, margins and regulatory status. Investors also track multiple on invested capital to measure fund returns.

Why it matters

Strategic MedTech acquirers have historically paid 4–8x revenue for growth-stage devices, with high-growth, platform, or first-in-category assets commanding premiums. Multiples compress in higher-rate environments.

Common pitfalls

•Misinterpreting high exit multiples as solely indicative of regulatory compliance, rather than market demand and financial performance.
•Failing to consider the impact of potential regulatory enforcement actions or product recalls on future exit multiples.
•Underestimating the due diligence regulatory burden for an acquiring company, which can affect the final valuation.
•Assuming that historical exit multiples are predictive of future valuations without accounting for evolving regulatory landscapes and technological advancements.

Sources

PitchBook MedTech reports · PitchBook
NVCA Model Documents · NVCA
Silicon Valley Bank - Healthcare Reports · SVB

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.